Mesenchymal stromal cells for treatment of the acute respiratory distress syndrome: The beginning of the story

Research output: Contribution to journalArticle

3 Citations (Scopus)
309 Downloads (Pure)

Abstract

In spite of decades of research, the acute respiratory distress syndrome (ARDS) continues to have an unacceptably high mortality and morbidity. Mesenchymal stromal cells (MSCs) present a promising candidate for the treatment of this condition and have demonstrated benefit in preclinical models. MSCs, which are a topic of growing interest in many inflammatory disorders, have already progressed to early phase clinical trials in ARDS. While a number of their mechanisms of effect have been elucidated, a better understanding of the complex actions of these cells may pave the way for MSC modifications, which might enable more effective translation into clinical practice.
Original languageEnglish
Pages (from-to)320-329
Number of pages10
JournalJournal of the Intensive Care Society
Volume16
Issue number4
Early online date21 May 2015
DOIs
Publication statusPublished - Nov 2015

Fingerprint Dive into the research topics of 'Mesenchymal stromal cells for treatment of the acute respiratory distress syndrome: The beginning of the story'. Together they form a unique fingerprint.

  • Cite this